Among all clinical trials listed at clinicaltrials.gov [29] for MET and HGF inhibitors four studies are open explicitly for patients with sarcomas and there are multiple studies open to patients with not further specified solid tumors, which could include also soft tissue sarcomas (June 2014). This evidence concerns the gene MET and soft tissue sarcoma.